Main Article Content
to help us achieve this. Formulation variables, such as, the levels of solubility enhancer (0-15% w/w of drug), ratio of the drug to the osmogents, coat thickness of the semipermeable membrane (SPM) and level of pore former (0-20% w/w of polymer) were found to effect the drug release from the developed formulations. Cellulose acetate (CA 398-10) was used as
the semipermeable membrane containing polyethylene glycol 400 as the Cplasticizer. ATL release was directly proportional to the level of the solubility enhancer, osmotic pressure generated by osmotic agent and level of pore former; however, was inversely proportional to the coat thickness of SPM. Drug release from developed formulations was independent of the pH and agitation intensities of release media. Burst strength of the exhausted shells decreased with increase in the level of pore former. The optimized formulations were subjected to stability studies as per International Conference on Harmonisation (ICH) guidelines, and formulations were found to be stable after 3 months study. Steady-state plasma levels of drug were predicted by the method of superposition.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
Khan MA, Bolton S, Kislalioglu MS. Optimization of process variables
for the preparation of ibuprofen coprecipitates with Eudragit S100. Int
J Pharm 1994;102:185-91.
Khan MA, Karnachi AA, Singh SK, Sastry SV, Kislalioglu SM,
BoRon S. Controlled release coprecipitates: Formulation considerations.
J Control Release 1995;37:132-41.
Singh SK, Dodge J, Durrani MJ, Khan MA. Optimization and
characterization of controlled release pellets coated with an
experimental latex: I. Anionic drug. Int J Pharm 1995;125:243-55.
Jonkman JH. Food Interactions with Sustained-Release Theophylline
Preparations 1: A Review. Clin Pharmacokinet 1989;16:162-79.
Santus G, Baker WR. Osmotic drug delivery: A review of the patent
literature. J Control Release 1995;35:1-21.
Verma RK, Garg S. Current status of drug delivery technologies and
future direction. Pharm Tech 2001;25:1-14.
Verma RK, Mishra B, Garg S. Osmotically controlled oral drug delivery.
Drug Dev lnd Pharm 2000;26:695-708.
Chao ST, Prather D, Pinson D, Coen P, Pruitt B, Knowles M, et al. Effect
of food on bioavailability of pseudoephedrine and brompheniramine
administered from a gastrointestinal therapeutic system. J Pharm Sci
Rose S, Nelson JF. A continuous long-term injector. Aust J Exp Biol
Theeuwes F. Elementary osmotic pump. J Pharm Sci 1975;64:1987-91.
Okimoto K, Miyake M, Ohnishi N, Rajewski RA, Uekama K,
Stella VJ. Design and evaluation of an osmotic pump tablet
(OPT) for prednisolone, a poorly water soluble drug, utilizing
(SBE) 7M - Î² - CD. Pharm Res 1998;15:1562-8.
Rao VM, Haslam JL, Stella VJ. Controlled and complete release of a
model poorly water-soluble drug, prednisolone, from hydroxypropyl
methycellulose matrix tablets using (SBE) 7M -Î²-cyclodextrin as a
solubilizing agent. J Pharm Sci 2001;90:807-16.
Herbig SM, Cardinal JR, Korsmeyer RW, Smith KL. Asymmetric-
membrane tablet coatings for osmotic drug delivery. J Control Release
Thombre AG, DeNoto AR, Gibbes DC. Delivery of glipizide from
asymmetric membrane capsules using encapsulated excipients.
J Control Release 1999;60:333-41.
Chen C, Lee D, Xie J. Controlled release formulation for water insoluble
drugs in which a passageway is formed in situ. US patent 5736159, 1998.
Zentner GM, Rork GS, Himmelstein KJ. The controlled porosity osmotic
pump. J Control Release 1985a;1:269-82.
Zentner GM, Rork GS, Himmelstein KJ. Osmotic flow through controlled
porosity films: An approach to delivery of water soluble compounds.
J Control Release 1985b;2:217-29.
Zentner GM, Rork GS, Himmelstein KJ. Controlled porosity osmotic
pump. US Patent 4968507, 1990.
McClelland GA, Zentner GM. Solubility modulated drug delivery system.
US patent 4946686, 1990.
Zentner GM, McClelland GA. Solubility modulated drug delivery device.
US patent 4994273, 1991.
Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic
and diastolic left ventricular function of nebivolol versus atenolol in
patients with uncomplicated essential hypertension. Am J Cardiol
Italian Pharmacopoeia. 10th ed. Rome, Italy: Istituto Poligrafico e Zecca
dello Stato; 1998. p. 610-1.
Caplar V, Mikotic-Mihun Z, Hoffman H, Kuffinec J, Kajfez F. Atenolol,
in Analytical Profiles of Drug Substances. In: Florey K, editor. Vol. 13.
New York: Academic Press; 1984. p. 1-25.
Ficarra R, Ficarra P, DiBella MR, Raneri D, Tommasini S, Calabro ML,
et al. Study of the inclusion complex of atenolol with Î²-cyclodextrins.
J Pharm Biomed Anal 2000;23:231-6.
Moneghini M, Carcano A, Zingone G, Perissutti B. Studies in dissolution
enhancement of atenolol. Int J Pharm 1998;175:177-83.
Serajuddin AT. Solid dispersion of poorly water-soluble drugs: Early
promises, subsequent problems, and recent breakthroughs. J Pharm
Ayer AD, Theeuwes F. Osmotic system with distribution zone for
dispensing beneficial agent. US Patent 4200098, 1980.
Ramakrishna N, Mishra B. Plastizer effects and comparative evaluation
of cellulose acetate and ethyl cellulose-HPMC combination coating as
semi-permeable membrane for oral osmotic pump of naproixen sodium.
Drug Dev Ind Pharm 2002;28:403-12.
Costa P, Lobo JM. Modeling and comparison of dissolution profiles. Eur
J Pharm Sci 2001;13:123-33.
Verma RK, Kaushal AM, Garg S. Development and evaluation of extended
release formulations of isosorbide mononitrate based on osmotic
technology. Int J Pharm 2003;263:9-24.
Ritschel WA. Biopharmaceutic and pharmacokinetic aspects in the
design of controlled release per-oral drug delivery systems. Drug Dev
Ind Pharm 1989;15:1073-103.
Sheskey P, Sackett G, Maher L, Lentz K, Tolle S, Polli J. Roll compaction
granulation of a controlled-release matrix tablet formulation containing
HPMC: Effect of Process Scale-up on Robustness of Tablets and Predicted
in Vivo Performance. Pharm Technol Tabletting and Granulation Year
book 1999. p. 6-21.
Sheskey P, Pacholke K, Sackett G, Maher L, Polli J. Roll compaction
granulation of a controlled release matrix tablet formulation
containing HPMC: Effect of process scale-up on robustness of tablets,
tablet stability and predicted in vivo performance. Part II. Pharm
Wadworth AN, Murdoch D, Brogden RN. Atenolol: A reappraisal of
its pharmacological properties and therapeutic use in cardiovascular
disorders. Drugs 1991;42:468-510.
Jeffers TA, Webster J, Petrie JC, Baker NP. Atenolol once-daily in
hypertension. Br J Pharmacol 1977;4:523-7.
Mehvar R, Gross ME, Kreamer RN. Pharmacokinetics of atenolol
enantiomers in humans and rats. J Pharm Sci 1990;79:881-5.